Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930162
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930162
Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
PUBLISHED:
PAGES: 278 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of metastatic castration-resistant prostate cancer (mCRPC) therapeutics Market
The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market is on a rapid growth trajectory, driven by the rising prevalence of advanced prostate cancer and the increasing demand for effective treatment options. The market was valued at USD 21.04 billion in 2025, projected to grow to USD 29.08 billion in 2026, and is expected to reach USD 91.85 billion by 2034, reflecting a CAGR of 15.46% during the forecast period. North America dominated the market in 2025, holding a 87.63% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and extensive research and development activities.
mCRPC is an advanced form of prostate cancer where tumors no longer fully respond to androgen deprivation therapy (ADT) and may spread to bones, lymph nodes, liver, lungs, and the brain. The aggressive nature of this cancer, combined with high morbidity and mortality, creates an urgent need for novel therapeutics. According to the World Cancer Research Fund, approximately 1.46 million new cancer cases were registered worldwide in 2022, emphasizing the growing demand for effective treatments.
Market Drivers
The market growth is propelled by several key factors:
- Robust drug pipelines: Pharmaceutical companies are actively developing next-generation androgen receptor inhibitors, PARP inhibitors, and CYP17 inhibitors to address the challenges of treatment-resistant prostate cancer.
- Collaborations and partnerships: For instance, in July 2022, Merck & Co., Inc. and Orion Corporation co-developed opevesostat (MK-5684/ODM-208), a CYP11A1 inhibitor for mCRPC.
- Therapeutic advancements: The launch of innovative combination therapies, such as pairing PARP inhibitors with AR inhibitors, significantly enhances treatment outcomes and combats resistance to ADT.
Market Restraints and Challenges
Despite the positive growth trajectory, several factors limit market expansion:
- Resistance to hormonal therapy: Over time, prostate cancer cells may adapt to androgen deprivation, reducing the effectiveness of conventional treatments. Mutations in androgen receptor pathways further contribute to resistance.
- Adverse side effects: Drugs like ZYTIGA (abiraterone) and enzalutamide are associated with joint swelling, hypokalemia, edema, diarrhea, and cardiovascular risks, which may lead to discontinuation and impact patient compliance.
Market Opportunities
- Emergence of radiotheranostics: Combining diagnostic imaging with targeted therapy allows personalized treatment, improving efficacy while minimizing side effects. For example, in November 2023, Clarity Pharmaceuticals initiated a Phase I/IIa trial for 64Cu/67Cu-SAR-bisPSMA in mCRPC patients.
- Growing adoption of combination therapies: Initiatives like Pfizer's TALAPRO-2 study in October 2024 show improved survival outcomes using PARP inhibitors with androgen receptor inhibitors.
Segmentation Analysis
By Drug Class
- Androgen receptor inhibitors dominate the market due to their role in blocking testosterone-driven cancer growth.
- GnRH agonists, GnRH receptor antagonists, microtubule inhibitors, and PARP inhibitors are projected to grow steadily due to new approvals and collaborations.
By Route of Administration
- Oral therapies dominate due to convenience, patient adherence, and better compliance.
- Parenteral therapies are growing through innovative clinical trials, such as Actinium-225 by POINT Biopharma (April 2024).
By Therapy
- Hormonal therapy leads, supported by widespread adoption of androgen deprivation therapy and availability of generics like Abiraterone Acetate.
- Targeted therapy and immunotherapy segments are expanding, while chemotherapy holds a smaller share due to side effects.
By Distribution Channel
- Hospital pharmacies dominate, owing to advanced healthcare infrastructure.
- Retail and online pharmacies are growing due to convenience and accessibility.
Regional Insights
- North America: Market size USD 11.31 billion in 2025, supported by the U.S. and Canada's robust healthcare systems, reimbursement policies, and R&D.
- Europe: Rising awareness campaigns and new diagnostic tools propel growth. For example, a new 'super test' developed in Cambridge (February 2025) enables early detection.
- Asia Pacific: Fastest-growing region with a CAGR of 13.6%, fueled by increasing prostate cancer prevalence and research funding initiatives.
- Latin America & Middle East & Africa: Moderate growth is anticipated, with increased government initiatives and expansion of cancer care centers.
Key Industry Players
Leading companies such as Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AbbVie Inc., and AstraZeneca dominate the market through extensive product portfolios, regulatory approvals, collaborations, and new launches. Notable developments include:
- August 2023: FDA approval of AKEEGA (niraparib + abiraterone) for mCRPC by Johnson & Johnson.
- June 2023: AstraZeneca's Lynparza (olaparib) approved for patients with BRCA mutations.
- December 2022: Novartis' Pluvicto approved by European Commission as targeted radioligand therapy.
Conclusion
The global metastatic castration-resistant prostate cancer therapeutics market is projected to grow from USD 21.04 billion in 2025 to USD 91.85 billion by 2034, at a CAGR of 15.46%. Market expansion is driven by the rising prevalence of advanced prostate cancer, robust R&D pipelines, innovative combination therapies, and emerging radiotheranostics. North America dominates, while Asia Pacific represents the fastest-growing region. Leading companies' strategic initiatives, product launches, and research collaborations are expected to sustain market growth and enhance treatment outcomes for mCRPC patients globally.
Segmentation By Drug Class
- Androgen Receptor Inhibitors
- Microtubule Inhibitors
- Gonadotropin Releasing Hormone (GnRH) Agonist
- Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- Others
By Route of Administration
- Oral
- Parenteral
By Therapy
- Chemotherapy
- Hormonal Therapy
- Targeted therapy
- Immunotherapy
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Geography
- North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
- U.S.
- Canada
- Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa ( By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
- GCC
- South Africa
- Rest of Middle East & Africa
Product Code: FBI112690
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
- 4.2. Pipeline Analysis, by Key Players
- 4.3. Overview of Alternative Therapies
- 4.4. Key Start-ups in the Market
- 4.5. New Product Launches, by Key Players
- 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.7. Impact of COVID-19 on the Market
5. Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Androgen Receptor Inhibitors
- 5.1.2. Microtubule Inhibitors
- 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Therapy
- 5.3.1. Chemotherapy
- 5.3.2. Hormonal Therapy
- 5.3.3. Targeted therapy
- 5.3.4. Immunotherapy
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Drug Stores & Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Androgen Receptor Inhibitors
- 6.1.2. Microtubule Inhibitors
- 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Therapy
- 6.3.1. Chemotherapy
- 6.3.2. Hormonal Therapy
- 6.3.3. Targeted therapy
- 6.3.4. Immunotherapy
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Drug Stores & Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Androgen Receptor Inhibitors
- 7.1.2. Microtubule Inhibitors
- 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Therapy
- 7.3.1. Chemotherapy
- 7.3.2. Hormonal Therapy
- 7.3.3. Targeted therapy
- 7.3.4. Immunotherapy
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Drug Stores & Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Androgen Receptor Inhibitors
- 8.1.2. Microtubule Inhibitors
- 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Therapy
- 8.3.1. Chemotherapy
- 8.3.2. Hormonal Therapy
- 8.3.3. Targeted therapy
- 8.3.4. Immunotherapy
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Drug Stores & Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Androgen Receptor Inhibitors
- 9.1.2. Microtubule Inhibitors
- 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Therapy
- 9.3.1. Chemotherapy
- 9.3.2. Hormonal Therapy
- 9.3.3. Targeted therapy
- 9.3.4. Immunotherapy
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Drug Stores & Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Androgen Receptor Inhibitors
- 10.1.2. Microtubule Inhibitors
- 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Therapy
- 10.3.1. Chemotherapy
- 10.3.2. Hormonal Therapy
- 10.3.3. Targeted therapy
- 10.3.4. Immunotherapy
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Drug Stores & Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Astellas Pharma Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Pfizer Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Johnson & Johnson Services, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Sanofi
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Ferring Pharmaceuticals Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. AbbVie Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. AstraZeneca
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Tolmar, Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Dendreon Pharmaceuticals LLC.
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Bayer AG
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
- 11.2.1. Astellas Pharma Inc.
Product Code: FBI112690
List of Tables
- Table 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 12: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 13: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 14: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 15: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 17: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 18: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 19: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 20: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 22: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 23: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 24: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 25: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 27: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 28: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 29: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 30: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034
- Figure 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2025 & 2034
- Figure 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 11: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 12: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 13: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 15: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country, 2025
- Figure 17: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 18: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 19: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 20: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 21: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 22: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 23: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 24: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 25: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 28: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 29: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 30: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 31: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 32: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 33: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion),by Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 38: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 39: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 40: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 41: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 42: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 43: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 44: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 45: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 48: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 49: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 50: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 51: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 52: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 53: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 55: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
Figure 57: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Share (%), By Company, 2025
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.